Building A Better Way Forward in Hemostasis
A Revolutionary Approach to Hemostasis Using Transcutaneous Auricular Neurostimulation (tAN®)
A Life-threatening Challenge in Need of Novel Treatment Options
Millions of patients suffer from excessive blood loss that significantly impact their quality of life and in many cases are life-threatening. The limited current treatment options come with a high price tag while they often fail to address bleeding quickly and effectively— leaving both patients and physicians desperately searching for better solutions.
Vagus Nerve Stimulation & The Neural Tourniquet
At Spark Biomedical, we understand the challenges you face in complex care scenarios.
A Proven Foundation for Breakthrough Innovation
Vagus nerve stimulation (VNS) is a well-established therapy for conditions like epilepsy, depression, inflammation, and stroke. Recent research has uncovered its potential to significantly reduce bleeding by up to 45% in preclinical models of soft tissue injury without causing systemic clotting or affecting blood pressure. This initial clinical research originating at Northwell Health spawned a novel treatment concept called The Neural Tourniquet™. Now, Five Liters, the hemostasis division of Spark Biomedical, is taking this work forward through our clinical work and on to commercialization.
How the Neural Tourniquet Works
The Neural Tourniquet leverages VNS to enhance localized clot formation without triggering systemic effects. Here’s how:
VNS increases thrombin production at the wound site, boosting clot formation without affecting systemic circulation.
VNS stimulates the vagus nerve to release acetylcholine, which activates platelets via a specific receptor (α7 nAChR). This “primes” the platelets for faster and stronger clotting when needed.
The preclinical data suggest a safe, localized response with no systemic risks, paving the way for innovative approaches to managing unwanted blood loss.
From Research to Reality
At Five Liters, the hemostasis division of Spark Biomedical, we are pioneering a novel clinical approach to hemostasis based on the Neural Tourniquet. Our proprietary transcutaneous auricular neurostimulation (tAN) device combines both vagus and trigeminal nerve stimulation and may be the groundbreaking treatment needed to quickly and effectively manage bleeding by activating the body's natural clotting mechanisms.
While initial Neural Tourniquet findings have shown promise in pre-clinical models, the next step is clinical trial work to confirm efficacy in human patients. This groundbreaking research could transform how physicians approach hemostasis.
Transcutaneous Auricular Neurostimulation (tAN®) Offers:
Non-invasive application
Easy-to-use, wearable technology.
Targeted hemostasis
Stimulates both the vagus and trigeminal nerves to regulate clotting factors
Enhanced patient outcomes
Aimed at reducing blood loss and improving quality of life
Publications & Clinical Trials
Clinical Trials
We are proud to collaborate with top institutions and researchers to explore the full potential of tAN for hemostasis.
Publications
Five Liters, the hemostasis division of Spark Biomedical is at the forefront of hemostasis and the Neural Tourniquet. Our work has been recognized in the following leading scientific journal:
Nature
Vagus nerve stimulation primes platelets and reduces bleeding in hemophilia A male mice
Our Clinical Trial Partners
Together, we’re shaping the future of blood loss management.
Stay at the forefront of Hemostasis Innovation
Join us on the journey to revolutionize bleeding management with the Transcutaneous Auricular Neurostimulation.
